Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Atezolizumab plus bevacizumab has become frontline therapy for unresectable HCC. The compatibility of atezolizumab/bevacizumab with liver-directed RT has not been reported. Methods: HCC patients treated with liver-directed RT and atezolizumab/bevacizumab between 1/2020–11/2021 were included. Toxicit...

Full description

Bibliographic Details
Main Authors: Gohar Shahwar Manzar, Brian Sandeep De, Chike Osita Abana, Sunyoung S. Lee, Milind Javle, Ahmed O. Kaseb, Jean-Nicolas Vauthey, Hop Sanderson Tran Cao, Albert C. Koong, Grace Li Smith, Cullen M. Taniguchi, Emma Brey Holliday, Prajnan Das, Eugene Jon Koay, Ethan Bernard Ludmir
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
radiation therapy
RT
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/14/8/1901

Internet

https://www.mdpi.com/2072-6694/14/8/1901

Similar Items